The year of the mega-merger continues with Merck & Co’s move to buy Schering-Plough for $41.1bn, with the intention of boosting its pipeline, entering new markets and creating a “powerful biologics presence”.
As Swiss firm Lonza announced last week that it has broken ground
at its second manufacturing site in Singapore, the region looks set
for growth in biologics manufacture with biological products due to
take centre stage in the pharma...
Determined to reduce costs in its manufacturing operations,
Schering-Plough has announced the loss of 1,100 positions in
manufacturing sites in Puerto Rico and New Jersey, aiming to save
$100m (€78.1m) a year.
Schering-Plough last week stopped enrollment in a Phase III trial
of its new anticancer agent, Sarasar (lonafarnib), after saying it
would not provide sufficient evidence of efficacy as a first-line
treatment for non-small cell lung...